Rsv subgroup a stabilized prefusion f antigen, rsv subgroup b stabilized prefusion f antigen
Sold as Abrysvo
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pfizer Laboratories (Pty) Ltd | Abrysvo | 120 μg | 590374 | Not determined | PIL |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Abrysvo EACH 0,5 ml DOSE CONTAINS RSV SUBGROUP A STABILIZED PREFUSION F ANTIGEN 60,0 µg RSV SUBGROUP B STABILIZED PREFUSION F ANTIGEN 60 µg | 120 μgPowder and solvent for solution for injection | 59037459/24.4/0374Approved 10 December 2024 | Registered | Not determined | PIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.